Hailey Burgoyne

Hailey Burgoyne

Auto-generated profile, based on publicly available information

Hailey Burgoyne

Research, US Department of Veterans Affairs Medical Center , Boise, Idaho , USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in Nano Energy
Verified
Journal Article
Open access
APAjay Pratap
Ajay Pratap
FKFereshteh Rajabi Kouchi
Fereshteh Rajabi Kouchi
HBHailey Burgoyne
Hailey Burgoyne
MCMichael Curtis
Michael Curtis
ARAttila Rektor
Attila Rektor
DEDavid Estrada
David Estrada

1 December 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JHJohn B Harley
John B Harley
SPSaiju Pyarajan
Saiju Pyarajan
EPElizabeth S Partan
Elizabeth S Partan
LELauren Epstein
Lauren Epstein
JWJason A Wertheim
Jason A Wertheim
Robert BonomoRobert Bonomo
Robert Bonomo
Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans. Methods: In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities. Results: VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities. Conclusions: VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide.